Although the efficacy of ICIs as single agents has shown no satisfactory results in GBM, it is necessary to evaluate their efficacy as complements of other active immunotherapeutic strategies, such as vaccines and/or immune-stimulating gene therapies, which promote T cell infiltration, the subsequent IFNγ production and PD-1/PD-L1 upregulation. The gene discussed is CD274; the disease is glioblastoma.